trending Market Intelligence /marketintelligence/en/news-insights/trending/JOVq4W5d71JOTXzYrKR0JA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

European Commission approves Johnson & Johnson's acquisition of Actelion

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

European Commission approves Johnson & Johnson's acquisition of Actelion

The European Commission approved Johnson & Johnson's acquisition of Actelion Ltd., marking the completion of all necessary approvals for the completion of the merger.

The transaction, which values each Actelion share at $280 apiece, is expected to be settled June 16.

As part of the transaction, Actelion will spin out its drug discovery operations and early stage clinical development assets into Idorsia Ltd. — a newly created Swiss biopharmaceutical company that will be listed on the SIX Swiss Exchange.

A Johnson & Johnson subsidiary will initially hold 9.9% of Idorsia, which can potentially increase up to 32% through a convertible note.